MA50674A - Benzamides substitués 1,3-thiazol-2-yl - Google Patents

Benzamides substitués 1,3-thiazol-2-yl

Info

Publication number
MA50674A
MA50674A MA050674A MA50674A MA50674A MA 50674 A MA50674 A MA 50674A MA 050674 A MA050674 A MA 050674A MA 50674 A MA50674 A MA 50674A MA 50674 A MA50674 A MA 50674A
Authority
MA
Morocco
Prior art keywords
thiazol
substituted benzamides
benzamides
substituted
Prior art date
Application number
MA050674A
Other languages
English (en)
Other versions
MA50674B1 (fr
Inventor
Nico Bräuer
Adam Davenport
Oliver Martin Fischer
Anne-Marie Godinho-Coelho
Jürgen Klar
Jens Nagel
Ioana Neagoe
Andrea Rotgeri
Antje Rottmann
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52015966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50674(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MA50674A publication Critical patent/MA50674A/fr
Publication of MA50674B1 publication Critical patent/MA50674B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MA50674A 2014-12-09 2015-12-07 Benzamides substitués 1,3-thiazol-2-yl MA50674B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14196954 2014-12-09

Publications (2)

Publication Number Publication Date
MA50674A true MA50674A (fr) 2021-03-31
MA50674B1 MA50674B1 (fr) 2022-11-30

Family

ID=52015966

Family Applications (2)

Application Number Title Priority Date Filing Date
MA41135A MA41135B1 (fr) 2014-12-09 2015-12-07 Benzamides substitués 1,3-thiazol-2-yl
MA50674A MA50674B1 (fr) 2014-12-09 2015-12-07 Benzamides substitués 1,3-thiazol-2-yl

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA41135A MA41135B1 (fr) 2014-12-09 2015-12-07 Benzamides substitués 1,3-thiazol-2-yl

Country Status (42)

Country Link
US (5) US10174016B2 (fr)
EP (2) EP3587417B9 (fr)
JP (2) JP6544665B2 (fr)
KR (2) KR20230098368A (fr)
CN (2) CN107207507B (fr)
AR (2) AR102948A1 (fr)
AU (1) AU2015359626B2 (fr)
BR (1) BR112017012327B1 (fr)
CA (1) CA2969952A1 (fr)
CL (1) CL2017001488A1 (fr)
CO (1) CO2017005742A2 (fr)
CR (2) CR20210108A (fr)
CU (1) CU24411B1 (fr)
CY (2) CY1124486T1 (fr)
DK (2) DK3587417T3 (fr)
DO (2) DOP2017000137A (fr)
EA (2) EA032312B1 (fr)
EC (1) ECSP17036253A (fr)
ES (2) ES2882952T3 (fr)
HR (2) HRP20220371T1 (fr)
HU (2) HUE058009T2 (fr)
IL (6) IL252665B (fr)
JO (2) JOP20150301B1 (fr)
LT (2) LT3587417T (fr)
MA (2) MA41135B1 (fr)
MX (2) MX387478B (fr)
MY (1) MY192690A (fr)
NI (1) NI201700073A (fr)
NZ (1) NZ761161A (fr)
PE (2) PE20220253A1 (fr)
PH (1) PH12017501079A1 (fr)
PL (2) PL3230281T3 (fr)
PT (2) PT3230281T (fr)
RS (2) RS62227B1 (fr)
SG (2) SG11201704717VA (fr)
SI (2) SI3230281T1 (fr)
SV (1) SV2017005461A (fr)
TN (1) TN2017000244A1 (fr)
TW (2) TWI780562B (fr)
UA (1) UA120382C2 (fr)
UY (1) UY36422A (fr)
WO (1) WO2016091776A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24411B1 (es) * 2014-12-09 2019-05-03 Bayer Ag Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN106588785A (zh) * 2016-12-02 2017-04-26 山东吉田香料股份有限公司 一种乙酰基吡嗪的制备方法
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
SG11202011010YA (en) * 2018-05-15 2020-12-30 Bayer Ag 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
MA52616A (fr) 2018-05-15 2021-03-24 Bayer Ag Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses
CN113164488A (zh) 2018-10-05 2021-07-23 盐野义制药株式会社 慢性咳嗽治疗用药物
IL282087B2 (en) * 2018-10-10 2025-11-01 Bellus Health Cough Inc 4-(imidazo[1,2-a]pyridin-3-yl)-benzamide derivatives for treating pruritus
DK3880678T3 (da) 2018-11-13 2025-06-10 Glaxosmithkline Intellectual Property No 3 Ltd Krystallinske former af p2x3-modulator methyl(s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholin-4-carboxylat
CA3131312A1 (fr) 2019-02-25 2020-09-03 Bellus Health Cough Inc. Traitement avec des modulateurs de p2x3
WO2020201398A1 (fr) 2019-04-05 2020-10-08 Syngenta Crop Protection Ag Composés de diazine-amide à action pesticide
WO2020208036A1 (fr) * 2019-04-11 2020-10-15 Syngenta Crop Protection Ag Composés diazine-amide à action pesticide
KR102923602B1 (ko) 2019-05-31 2026-02-06 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 피리도피리미딘 유도체
MA56022A (fr) 2019-05-31 2022-04-06 Chiesi Farm Spa Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3
EP3757103A1 (fr) * 2019-06-27 2020-12-30 Bayer AG Analogues de 3-(5-méthyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl}benzamide pour le traitement des maladies neurogeniques
CN113082023B (zh) * 2019-12-23 2024-03-01 武汉朗来科技发展有限公司 P2x3抑制剂和p2x4抑制剂的药物组合及其应用
WO2021238834A1 (fr) * 2020-05-25 2021-12-02 中国医药研究开发中心有限公司 Composé arylformamide et son procédé de préparation et son utilisation médicale
WO2022063205A1 (fr) * 2020-09-24 2022-03-31 中国医药研究开发中心有限公司 Composé aryl formamide, son procédé de préparation et ses utilisations médicales
EP4223751A4 (fr) * 2020-09-30 2024-11-27 Humanwell Healthcare (Group) Co., Ltd. Composé benzamide et son utilisation
WO2022112490A1 (fr) 2020-11-27 2022-06-02 Chiesi Farmaceutici S.P.A. Dérivés d'amino-quinazoline utilisés en tant qu'inhibiteurs de p2x3
JP2023550830A (ja) 2020-11-27 2023-12-05 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｐ２ｘ３阻害剤としての（アザ）キノリン４－アミン誘導体
CN116745284A (zh) 2020-11-27 2023-09-12 奇斯药制品公司 作为p2x3抑制剂的酞嗪衍生物
CN114591317A (zh) * 2020-12-04 2022-06-07 武汉人福创新药物研发中心有限公司 P2x3抑制剂及其用途
WO2022253945A1 (fr) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Formes posologiques pharmaceutiques comprenant du 3-(5-méthyl-1,3-thiazol-2-yl)-5-[(3r)-tétrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluorométhyl)pyrimidin-5-yl]éthyl}-benzamide
WO2022253943A1 (fr) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Formes cristallines de 3-(5-méthyl-1,3-thiazol-2-yl)-5-[(3r)-tétrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl}-benzamide
CN116396285A (zh) * 2022-01-04 2023-07-07 上海华汇拓医药科技有限公司 氘代四氢呋喃类化合物制备及其应用
US12024285B1 (en) 2022-03-10 2024-07-02 Skypad Tech, Inc. Modular mobility system including thrusters movably connected to a support structure
EP4501929A4 (fr) * 2022-03-29 2026-04-08 Humanwell Healthcare Group Co Ltd Composé inhibiteur de p2x3, sel de celui-ci, polymorphe de celui-ci et utilisation associée
WO2024131948A1 (fr) * 2022-12-22 2024-06-27 人福医药集团股份公司 Procédé de préparation d'un inhibiteur de p2x3
JP2026517300A (ja) 2023-05-22 2026-05-28 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｐ２ｘ３阻害剤を調製するための方法および中間体
CN117777048B (zh) * 2023-09-25 2024-09-20 上海科利生物医药有限公司 一种手性2-羟甲基吗啉-4-羧酸叔丁酯的制备方法
AU2024410803A1 (en) * 2023-12-29 2026-07-02 Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. Solid dispersion of p2x3 receptor antagonist and preparation process thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5198256B2 (ja) 2005-05-04 2013-05-15 エボテク エージー 縮合複素環式化合物、並びにそれらの組成物及び使用
ES2596706T3 (es) 2006-06-29 2017-01-11 F. Hoffmann-La Roche Ag Arilamidas con sustitución de tetrazol
US8501933B2 (en) * 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
JP5084839B2 (ja) * 2006-11-09 2012-11-28 エフ．ホフマン−ラ ロシュ アーゲー チアゾール及びオキサゾール置換アリールアミド
WO2008123963A1 (fr) 2007-04-02 2008-10-16 Renovis, Inc. Composés hétérocycliques fusionnés avec pyrid-2-yl, et leurs compositions et utilisations
US8076345B2 (en) 2007-04-17 2011-12-13 Evotec Ag 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
TW200906826A (en) * 2007-06-12 2009-02-16 Genelabs Tech Inc Anti-viral inhibitors and methods of use
EP2215048B1 (fr) 2007-10-31 2015-10-28 Merck Sharp & Dohme Corp. Antagonistes du récepteur p2x3 utilisés dans le traitement de la douleur
WO2009058298A1 (fr) 2007-10-31 2009-05-07 Merck & Co., Inc. Antagonistes du récepteur p2x3 utilisés dans le traitement de la douleur
BR122019016794B8 (pt) 2007-12-17 2021-07-27 Hoffmann La Roche derivados de arilamida substituídos por tetrazol, composição farmacêutica que os compreende e seu uso no tratamento de uma condição inflamatória e/ou autoimune
ES2570628T3 (es) 2007-12-17 2016-05-19 Hoffmann La Roche Nuevas arilamidas con sustitución imidazol
KR101405746B1 (ko) 2007-12-17 2014-06-10 에프. 호프만-라 로슈 아게 트리아졸 치환된 아릴아미드 유도체 및 ｐ２ｘ３ 및/또는 ｐ２ｘ２／３ 퓨린성 수용체 길항제로서의 용도
DK2234976T3 (da) 2007-12-17 2013-06-24 Hoffmann La Roche Nye pyrazol-substituerede arylamider
WO2009110985A2 (fr) * 2008-02-29 2009-09-11 Renovis, Inc. Composés amides, compositions à base de ces composés et leurs utilisations
US20110237578A1 (en) 2008-09-18 2011-09-29 Zhi-Liang Wei Amide compounds, compositions and uses thereof
CA2741666C (fr) * 2008-10-31 2017-04-11 Merck Sharp & Dohme Corp. Antagonistes du recepteur p2x3 pour le traitement de la douleur
BRPI0922645A2 (pt) 2008-12-16 2019-09-24 Hoffmann La Roche "arilamidas tiadiazol substituídas".
EP2445868B1 (fr) 2009-06-22 2013-12-18 F.Hoffmann-La Roche Ag Amides biphényles utiles en tant que modulateurs des récepteurs p2x3 et/ou p2x2/3
CA2754654A1 (fr) 2009-06-22 2010-12-29 F. Hoffmann-La Roche Ag Nouveaux arylamides substitues par oxazolone et pyrrolidinone
KR101781663B1 (ko) 2010-01-13 2017-09-25 템페로 파마슈티칼즈, 인크. 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법
WO2013009810A1 (fr) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Méthodes de traitement
US9562041B2 (en) * 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
JP6254169B2 (ja) 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
KR102120513B1 (ko) 2013-01-31 2020-06-08 네오메드 인스티튜트 이미다조피리딘 화합물 및 이의 용도
CU24411B1 (es) 2014-12-09 2019-05-03 Bayer Ag Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
US10183937B2 (en) * 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
MA52616A (fr) 2018-05-15 2021-03-24 Bayer Ag Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses
SG11202011010YA (en) 2018-05-15 2020-12-30 Bayer Ag 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EP3757103A1 (fr) 2019-06-27 2020-12-30 Bayer AG Analogues de 3-(5-méthyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl}benzamide pour le traitement des maladies neurogeniques

Also Published As

Publication number Publication date
HRP20220371T1 (hr) 2022-05-13
RS63014B1 (sr) 2022-04-29
US20190185466A1 (en) 2019-06-20
SG10202012274RA (en) 2021-01-28
US10174016B2 (en) 2019-01-08
IL269467B (en) 2020-08-31
CN107207507B (zh) 2020-11-06
DOP2017000137A (es) 2017-07-31
PE20180227A1 (es) 2018-01-31
JP6544665B2 (ja) 2019-07-17
JOP20230073A1 (ar) 2016-06-09
KR20170093203A (ko) 2017-08-14
EA034273B1 (ru) 2020-01-23
BR112017012327B1 (pt) 2023-04-11
CU24411B1 (es) 2019-05-03
EP3230281B1 (fr) 2021-05-26
CY1125083T1 (el) 2023-06-09
US20180118731A1 (en) 2018-05-03
AU2015359626A1 (en) 2017-06-29
ES2908822T3 (es) 2022-05-04
IL275183B (en) 2021-06-30
IL252665B (en) 2019-10-31
DK3587417T3 (da) 2022-03-28
MX2020005909A (es) 2021-10-28
EP3587417B1 (fr) 2022-01-05
RS62227B1 (sr) 2021-09-30
UA120382C2 (uk) 2019-11-25
TW201629053A (zh) 2016-08-16
JP6647371B2 (ja) 2020-02-14
JOP20150301B1 (ar) 2023-09-17
MX2017007658A (es) 2018-08-01
PH12017501079A1 (en) 2017-10-18
IL269467A (en) 2019-11-28
CO2017005742A2 (es) 2017-09-20
IL269468A (en) 2019-11-28
NZ733108A (en) 2022-03-25
SV2017005461A (es) 2018-04-30
HUE058009T2 (hu) 2022-06-28
CN107207507A (zh) 2017-09-26
IL269468B (en) 2020-06-30
IL252665A0 (en) 2017-08-31
PL3587417T3 (pl) 2022-06-13
EP3587417A1 (fr) 2020-01-01
BR112017012327A2 (pt) 2018-02-27
BR112017012327A8 (pt) 2021-02-23
IL283979B (en) 2022-04-01
US20230053411A1 (en) 2023-02-23
US20200131169A1 (en) 2020-04-30
CY1124486T1 (el) 2022-07-22
EA201891120A1 (ru) 2018-10-31
CN110256418A (zh) 2019-09-20
KR102548799B1 (ko) 2023-06-27
HRP20211002T1 (hr) 2021-09-17
US10472354B2 (en) 2019-11-12
IL269661A (en) 2019-11-28
AR102948A1 (es) 2017-04-05
IL269661B (en) 2020-07-30
LT3230281T (lt) 2021-07-12
EP3230281A1 (fr) 2017-10-18
CR20170242A (es) 2018-02-02
KR20230098368A (ko) 2023-07-03
HUE055290T2 (hu) 2021-11-29
US10202369B2 (en) 2019-02-12
PL3230281T3 (pl) 2021-12-13
IL275183A (en) 2020-07-30
CL2017001488A1 (es) 2018-02-23
CA2969952A1 (fr) 2016-06-16
TWI716371B (zh) 2021-01-21
EP3587417B9 (fr) 2022-03-30
US11142523B2 (en) 2021-10-12
NI201700073A (es) 2017-10-24
PE20220253A1 (es) 2022-02-16
JP2019059742A (ja) 2019-04-18
TW202130637A (zh) 2021-08-16
ECSP17036253A (es) 2017-06-30
NZ761161A (en) 2024-04-26
LT3587417T (lt) 2022-02-10
CN110256418B (zh) 2023-01-20
PT3587417T (pt) 2022-03-16
SG11201704717VA (en) 2017-08-30
EA201791261A1 (ru) 2017-12-29
MA50674B1 (fr) 2022-11-30
US20180093980A1 (en) 2018-04-05
SI3230281T1 (sl) 2021-08-31
JP2017537122A (ja) 2017-12-14
MX387478B (es) 2025-03-18
EA032312B1 (ru) 2019-05-31
MY192690A (en) 2022-09-01
TWI780562B (zh) 2022-10-11
AR119761A2 (es) 2022-01-12
PT3230281T (pt) 2021-08-19
CU20170077A7 (es) 2017-11-07
IL283979A (en) 2021-07-29
DOP2018000182A (es) 2018-09-15
SI3587417T1 (sl) 2022-04-29
CR20210108A (es) 2021-04-27
MA41135B1 (fr) 2021-10-29
UY36422A (es) 2016-06-30
WO2016091776A1 (fr) 2016-06-16
DK3230281T3 (da) 2021-08-16
MX377651B (es) 2025-03-11
TN2017000244A1 (en) 2018-10-19
ES2882952T3 (es) 2021-12-03
AU2015359626B2 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
IL283979B (en) 3,1-thiazol-2-yl converted benzamides
FIC20230006I1 (fi) Vutrisiraani
PL3345230T3 (pl) Podwójny perowskit
DK3130649T3 (da) Haloolefin-baseret sammensætning
FR3024363B1 (fr) Composition thermogelifiable
DK3110442T3 (da) Modificerede meningokok-fhbp-polypeptider
KR20180084876A (ko) 내플라즈마성 부재
EP3465295A4 (fr) Empilement de polariseurs
DE112015001664A5 (de) Betätigungsaktuator
PT3092003T (pt) Novo anticorpo anti-netrina 1
CL2017000639A1 (es) Composición
DE112015005041A5 (de) Gargerätevorrichtung
HUE059386T2 (hu) Új heterociklusos antiösztrogének
DE102014000623A8 (de) Halbhohlnietelement
EP3384016A4 (fr) Phagémides modifiés
EP3236746C0 (fr) Composition
DK3199160T3 (da) Vandig sammensætning
DK3217964T3 (da) Sammensætning
FR3019552B1 (fr) Composition filmogene
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
DE112015001633A5 (de) Betätigungsaktuator
FR3020039B1 (fr) Aerodyne
ES1098331Y (es) Abaco mejorado
DE102014112481A8 (de) Axialfederanordnung
DE112014006499A5 (de) Umfüllbehälter